Publications by authors named "A Polli"
Introduction: Fibromyalgia syndrome (FMS) causes significant pain, disability, and costs among patients. It is paramount that healthcare professionals have an updated knowledge of its characteristics and Clinical Practice Guidelines (CPGs).
Objectives: To determine the knowledge, adherence to CPGs, and confidence of Italian physiotherapists in managing patients with FMS, explore barriers to the implementation of CPG' recommendations, compare groups' adherence to CPGs, and determine which variables explained most of the participants' knowledge.
Background: Up to 30% of people infected with SARS-CoV-2 report disabling symptoms 2 years after the infection. Over 100 persistent symptoms have been associated with Post-Acute COVID-19 Symptoms (PACS) and/or long-COVID, showing a significant clinical heterogeneity. To develop effective, patient-targeted treatment, a better understanding of underlying mechanisms is needed.
View Article and Find Full Text PDFBackground: BRAF inhibitors plus MEK inhibitors (BRAFi/MEKi) and immune checkpoint inhibitors (CPIs) are approved for BRAF V600-mutant advanced melanoma. Combinations of BRAFi/MEKi with CPIs may further improve outcomes and could offer additional treatment strategies.
Methods: STARBOARD (NCT04657991) is a phase III study with an initial safety lead-in (SLI) phase conducted to determine the recommended phase III dose (RP3D) for encorafenib in combination with binimetinib and pembrolizumab.
Article Synopsis
- Next-generation ALK tyrosine kinase inhibitors (TKIs) like alectinib, brigatinib, and lorlatinib show better progression-free survival compared to chemotherapy or crizotinib for first-line treatment of ALK-positive advanced non-small cell lung cancer (NSCLC).
- The study conducted a network meta-analysis (NMA) to compare the efficacy of lorlatinib with other ALK TKIs, focusing on progression-free survival and other outcomes, using data from ten trials.
- Results indicated lorlatinib significantly improved progression-free survival compared to both alectinib and brigatinib, supporting its use as an effective first-line treatment for this type of lung cancer.